ertapenem/zidebactam (WCK 6777) / Wockhardt - LARVOL DELTA

This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis (clinicaltrials.gov) - P2 | N=279 | Not yet recruiting | Sponsor: Wockhardt

New P2 trial • Infectious Disease • Nephrology

In vitro potency of novel ertapenem/zidebactam combination (WCK 6777) against carbapenemase-producing Enterobacterales collected across India. (PubMed, JAC Antimicrob Resist) - "MICs of ertapenem/zidebactam and comparator agents (carbapenems, imipenem/relebactam, ceftazidime/avibactam and aztreonam/avibactam) were determined by broth microdilution method. The enhanced activity of ertapenem/zidebactam is attributed to zidebactam's dual mechanism, β-lactamase inhibition and high-affinity PBP2 binding, enabling effective coverage despite complex resistance mechanisms. Its once-daily dosing supports its potential as an OPAT-enabling therapeutic option and warrant further clinical development."

Journal • Preclinical • Infectious Disease • Pneumonia

In vitro activity of once-daily, investigational antibiotic, ertapenem/zidebactam (WCK 6777) against carbapenemase-producing E. coli and K. pneumoniae collected from Indian tertiary care hospitals (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease • Pneumonia

A Phase 1, randomised, double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacokinetics (PK) of intravenous ertapenem (ERT) with zidebactam (ZID) in combination (WCK 6777) in healthy adult subjects (ESCMID Global 2025) - No abstract available

Clinical • P1 data • PK/PD data

In vitro activity of once-daily, investigational combination, ertapenem/zidebactam (WCK 6777) against cefiderocol non-susceptible E. coli harbouring NDM and PBP3 insertions (ESCMID Global 2025) - No abstract available

Preclinical

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Intravenous Ertapenem (ERT) with Zidebactam (ZID) in Combination (WCK 6777) in Healthy Adult Subjects (ESCMID Global 2025) - No abstract available

Clinical

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777) (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Completed

Trial completion • Infectious Disease

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777) (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Infectious Disease

Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777) (clinicaltrials.gov) - P1 | N=52 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Combination therapy • New P1 trial • Infectious Disease